- Home
- PIII vs ATHA Comparison
PIII vs ATHA Comparison
Compare PIII & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | ATHA |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 18.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PIII | ATHA |
|---|---|---|
| Price | $5.30 | $3.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | 9.8K | ★ 25.4K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.97 | $2.20 |
| 52 Week High | $14.50 | $6.68 |
Technical Indicators
Market Signals| Indicator | PIII | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 38.64 |
| Support Level | $5.14 | $3.83 |
| Resistance Level | $5.62 | $4.74 |
| Average True Range (ATR) | 0.48 | 0.33 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 9.86 | 4.27 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.